Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
15
03
2022
accepted:
22
08
2022
pubmed:
18
10
2022
medline:
22
11
2022
entrez:
17
10
2022
Statut:
ppublish
Résumé
Attempts to reduce the human immunodeficiency virus type 1 (HIV-1) reservoir and induce antiretroviral therapy (ART)-free virologic control have largely been unsuccessful. In this phase 1b/2a, open-label, randomized controlled trial using a four-group factorial design, we investigated whether early intervention in newly diagnosed people with HIV-1 with a monoclonal anti-HIV-1 antibody with a CD4-binding site, 3BNC117, followed by a histone deacetylase inhibitor, romidepsin, shortly after ART initiation altered the course of HIV-1 infection ( NCT03041012 ). The trial was undertaken in five hospitals in Denmark and two hospitals in the United Kingdom. The coprimary endpoints were analysis of initial virus decay kinetics and changes in the frequency of CD4
Identifiants
pubmed: 36253609
doi: 10.1038/s41591-022-02023-7
pii: 10.1038/s41591-022-02023-7
pmc: PMC10189540
mid: NIHMS1880982
doi:
Substances chimiques
Anti-Retroviral Agents
0
Depsipeptides
0
romidepsin
CX3T89XQBK
Banques de données
ClinicalTrials.gov
['NCT03041012']
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2424-2435Subventions
Organisme : Medical Research Council
ID : MR/L00528X/1
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : P01 AI100148
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI164565
Pays : United States
Organisme : CIHR
Pays : Canada
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Nature. 2017 Mar 23;543(7646):559-563
pubmed: 28289286
Nature. 2012 Jul 25;487(7408):482-5
pubmed: 22837004
AIDS. 2017 Jul 31;31(12):1665-1667
pubmed: 28463884
PLoS Pathog. 2020 Jun 3;16(6):e1008378
pubmed: 32492044
Nat Med. 2020 Feb;26(2):222-227
pubmed: 32015556
J Virus Erad. 2020 Jul 18;6(3):100004
pubmed: 33251022
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Nat Protoc. 2017 Oct;12(10):2029-2049
pubmed: 28880280
Nat Med. 2019 Apr;25(4):547-553
pubmed: 30936546
J Infect Dis. 2022 Mar 2;225(5):856-861
pubmed: 34562096
Sci Transl Med. 2019 Oct 9;11(513):
pubmed: 31597754
Nat Commun. 2021 Jan 8;12(1):165
pubmed: 33420062
J Virol. 2014 Dec;88(24):14050-6
pubmed: 25253352
HIV Clin Trials. 2012 Nov-Dec;13(6):301-7
pubmed: 23195668
Nature. 2022 Jun;606(7913):368-374
pubmed: 35418681
Immunity. 2012 Mar 23;36(3):491-501
pubmed: 22406268
Lancet HIV. 2016 Oct;3(10):e463-72
pubmed: 27658863
Cell Rep. 2017 Oct 17;21(3):813-822
pubmed: 29045846
Vaccines (Basel). 2019 Jul 25;7(3):
pubmed: 31349655
Lancet HIV. 2014 Oct;1(1):e13-21
pubmed: 26423811
PLoS Pathog. 2012;8(4):e1002615
pubmed: 22496643
Nature. 2015 Jun 25;522(7557):487-91
pubmed: 25855300
Nat Rev Immunol. 2020 Aug;20(8):471-482
pubmed: 32051540
Nat Med. 2021 Dec;27(12):2085-2098
pubmed: 34848888
Science. 2016 May 20;352(6288):997-1001
pubmed: 27199429
J Exp Med. 2019 Oct 7;216(10):2253-2264
pubmed: 31350309
Nat Med. 2014 Feb;20(2):139-42
pubmed: 24412925
PLoS Pathog. 2014 Apr 10;10(4):e1004071
pubmed: 24722454
J Infect Dis. 2020 Mar 16;221(7):1135-1145
pubmed: 31776569
Proc Natl Acad Sci U S A. 2020 Aug 4;117(31):18754-18763
pubmed: 32690707
Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):E8958-E8967
pubmed: 30185556
Can J Cardiol. 2021 Sep;37(9):1322-1331
pubmed: 33276049
BMJ. 2019 Jul 8;366:l4179
pubmed: 31285198
PLoS One. 2010 Feb 23;5(2):e9390
pubmed: 20186346
PLoS Pathog. 2015 Sep 17;11(9):e1005142
pubmed: 26379282
Lancet HIV. 2019 Apr;6(4):e259-e268
pubmed: 30885693
PLoS Pathog. 2014 Nov 13;10(10):e1004473
pubmed: 25393648
Cell. 2015 May 21;161(5):1035-1045
pubmed: 25976835
Nat Med. 2009 Aug;15(8):893-900
pubmed: 19543283
Nat Commun. 2014 Nov 10;5:5407
pubmed: 25382623
Lancet. 2005 Aug 13-19;366(9485):549-55
pubmed: 16099290
AIDS. 2016 Jan 28;30(3):343-53
pubmed: 26588174
Nat Med. 2017 Nov;23(11):1271-1276
pubmed: 28967921
Science. 2016 May 20;352(6288):1001-4
pubmed: 27199430
Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):18002-18009
pubmed: 32665438
Science. 2011 Sep 16;333(6049):1633-7
pubmed: 21764753
J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):140-7
pubmed: 24457632
Cell Host Microbe. 2016 Sep 14;20(3):368-380
pubmed: 27545045
Lancet. 2020 Mar 14;395(10227):888-898
pubmed: 32085823
Nat Med. 2021 Oct;27(10):1718-1724
pubmed: 34621054
Front Immunol. 2021 Jul 29;12:708355
pubmed: 34394110
mBio. 2021 Jun 29;12(3):e0056021
pubmed: 34154408
Nat Commun. 2022 Feb 2;13(1):630
pubmed: 35110562
mBio. 2017 Jul 11;8(4):
pubmed: 28698276
Expert Rev Anti Infect Ther. 2016;14(5):447-50
pubmed: 26953620
AIDS. 2008 Jun 19;22(10):1131-5
pubmed: 18525258
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
J Infect Dis. 2014 Sep 1;210(5):728-35
pubmed: 24620025
Nature. 2019 Feb;566(7742):120-125
pubmed: 30700913
Lancet Microbe. 2022 Mar;3(3):e203-e214
pubmed: 35544074
Nature. 2018 Sep;561(7724):479-484
pubmed: 30258136
Nat Med. 2018 Nov;24(11):1701-1707
pubmed: 30258217
Clin Infect Dis. 2014 Nov 1;59(9):1312-21
pubmed: 25073894
Nat Commun. 2022 Feb 3;13(1):662
pubmed: 35115533
Front Immunol. 2020 May 06;11:823
pubmed: 32435247
J Pharmacol Pharmacother. 2010 Jul;1(2):100-7
pubmed: 21350618
Elife. 2016 Nov 15;5:
pubmed: 27855060
Nat Med. 2017 Feb;23(2):185-191
pubmed: 28092665
PLoS One. 2014 Apr 07;9(4):e93330
pubmed: 24710023
J Infect Dis. 2021 Aug 16;224(4):648-656
pubmed: 34398236